Preliminary evaluation of melatonin in the kindling model of epilepsy
During the past decades, epilepsy syndrome has been depicted across India as well as worldwide and this leads to increasing mortality and morbidity rate. Researchers are trying to investigate the responsible causes and risk factors for seizure occurrence. Epilepsy is a chronic disorder which is derived from a Latin word ‘sacire’ meaning ‘convulsive attack’ and is expressed as a paroxysmal experience appointed to atypical, unnecessary or concurrent neuronal bustle in the brain. The treatment of epilepsy involves the use of anti-epileptic drugs i.e. Sodium valproate, phenytoin, carbamazepine. Despite being treated with the available anti-convulsant drugs, this disease is still prevalent worldwide. So, as an adjuvant treatment melatonin exhibit an anti-epileptic activity in several animal models of epilepsy. However, its anti-epileptic potential has yet to be evaluated in Pentylenetetrazole (PTZ) induced model of epilepsy through kindling phenomenon. Rats were injected with a dose of (35-55 mg/kg) of pentylenetetrazole (PTZ) up to twenty days in alternate days. Observed the convulsive behavior of rats for thirty minutes immediately after PTZ injection. The entire treatment schedule includes the administration of melatonin (75 mg/kg) one hour prior to the PTZ administration. Sodium valproate was used as standard drug for this kindling model of epilepsy.
Keywords: Pentylenetetrazole, Melatonin, Sodium valproate, Gamma-amino butyric acid
2. Noronha AL, Borges MA, Marques LH, Zanetta DM, Fernandes PT, De Boer H, Espindola J, Miranda CT, Prilipko L, Bell GS, Sander JW “Prevalence and pattern of epilepsy treatment in different socioeconomic classes in Brazil”, Epilepsia, 2007; 48(5):880-5.
3. Megiddo I, Colson A, Chisholm D, Dua T, Nandi A, Laxminarayan R “Health and economic benefits of public financing of epilepsy treatment in India: An agent-based simulation model.” Epilepsia, 2016; 57(3):464-474.
4. Warner TT, Hammans SR. “Practical guide to neurogenetics”, Philadelphia: Saunders/Elsevier, 2009.
5. Annegers JF, Grabow JD, Groover RV, Laws ER, Elveback LR, Kurland LT. “Seizures after head trauma. A population stud”, Neurology, 1980; 30(7):683.
6. Behrens E, Schramm J, Zentner J Konig R. “Surgical and neurological complications in a series of epilepsy surgery procedures”, Neurosurgery, 1997; 41(1):1-10.
7. Ochoa J G, Riche W. “Antiepileptic drugs: an overview”, eMedicine journal, 2004.
8. Lowenstein DH. “Seizures and epilepsy”, Harrison’s principles of internal medicine, 2005; 16(2):2357.
9. Tomson T, Battino D. “Teratogenic effects of anti-epileptic drugs”, Lancet Neurol, 2012; 11:803-13.
10. Zawab A, Carmody J. “Safe use of sodium valproate”, Australian prescriber, 2014; 37(4).
11. Lowrey PL, Takahashi JS “Mammalian circadian biology: elucidating genome-wide levels of temporal organization.” Annu. Rev Genomics Hum Genet 2004; 5:407-4.
12. Ueda HR, Hayashi S, Chen W, Sano M, Machida M, Shigeyoshi Y, Iino M, Hashimoto S. “System-level identification of transcriptional circuits underlying mammalian circadian clocks”, Nature genetics, 2005; 37(2):187.
13. Chowdhury I, Sengupta A, Maitra SK. “Melatonin: fifty years of scientific journey from the discovery in bovine pineal gland to delineation of functions in human”.
14. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. “Melatonin—A pleiotropic, orchestrating regulator molecule.”Progress in neurobiology 2011; 93(3):350-84.
15. Singh M, Jadhav HR, “Melatonin: functions and ligands. Drug discovery today”, 2014; 19(9):1410-8.
16. Mahmood D, Muhammad BY, Alghani M, Anwar J, el-Lebban N, Haider M. “Advancing role of melatonin in the treatment of neuropsychiatric disorders”, Egyptian Journal of Basic and Applied Sciences, 2016; 3(3):203-18.
17. Radogna F, Diederich M, Ghibelli L. “Melatonin: a pleiotropic molecule regulating inflammation”, Biochemical pharmacology 2010; 80(12):1844-52.
18. Goldensohn ES, Porter RJ, Schwartzkroin PA. “The American Epilepsy Society: an historic perspective on 50 years of advances in research”. Epilepsia, 1997; 38(1):124-50.
19. Babb TL “Pathological findings in epilepsy: Surgical treatment of the epilepsies”, 1987; 511-40.
20. Mayer ML, Westbrook GL. “Permeation and block of N methyl-D-aspartic acid receptor channels by divalent cations in mouse cultured central neurones”, The Journal of physiology, 1987; 394(1):501-27.
21. Tanabe Y, Masu M, Ishii T, Shigemoto R, Nakanishi S, “A family of metabotropic glutamate receptors”, Neuron, 1992; 8(1):169-79.
22. Tanabe Y, Masu M, Ishii T, Shigemoto R, Nakanishi S. “A family of metabotropic glutamate receptors”, Neuron, 1993; 8(1):169-79.
23. Nicoll R A, Malenka R C, Kauer JA. “Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system”, Physiological reviews, 70(2):513-565, 1990.
24. Depaulis ACMC, Deransart C, Vergnes M, Marescaux C “GABAergic mechanisms in generalized epilepsies: the neuroanatomical dimension”, Revue neurologique 1997; 153:S8-13.
25. Lason W, Chlebicka M, Rejdak K. “Research advances in basic mechanisms of seizures and antiepileptic drug action.” Pharmacological Reports, 2013; 65(4):787-80.
26. Bloom FE, Iversen LL. “Localizing 3H-GABA in nerve terminals of rat cerebral cortex by electron microscopic autoradiography”, Nature 1971; 229(5287):628-630.
27. Sieghart W. “Structure, pharmacology, and function of GABAA receptor subtypes”, Adv Pharmacol, 2006; 54:231-263.
28. Bowery NG. “Historical perspective and emergence of the GABAB receptor,” Adv Pharmacol, 2010; 58:1-18.
29. Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA. “Neurosteroid modulation of GABAA receptors”. Prog Neurobiol, 2003; 7(1):67-80.
30. Hosie AM, Wilkins ME, da Silva HM, Smart TG. “Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites”. Nature 2006; 444(7118):486-489.
31. Wang M. “Neurosteroids and GABA-A receptor function”, Front Endocrinol (Lausanne), 2011; 2:44.
32. “National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals Guide for the care and use of laboratory animals”, 8th edn. National Academies Press, Washington, 2011.
33. Hoeller AA, de Carvalho CR, Franco PL, Formolo DA, Imthon AK, dos Santos HR, Eidt I, Souza GR, Constantino LC, Ferreira CL, Prediger RD. “Behavioral and Neurochemical Consequences of Pentylenetetrazol-Induced Kindling in Young and Middle-Aged Rats.” Pharmaceuticals, 2017; 10(3):75.
34. Luttjohann A, Fabene PF, van Luijtelaar G. “A revised Racine’s scale for PTZ-induced seizures in rats”, Physiol Behav, 2009; 98:579-586.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).